Background: Drug survival in a real-life setting is critical to long-term use of biologics for
psoriasis. Objective: We describe our 12-year experience with biologics in psoriasis …

Abstract Background Approximately 20–30% of patients with psoriasis treated with anti‐
tumour necrosis factor α (TNFα) agents will discontinue treatment within 2 years due to loss …

Objective To compare the efficacy of ustekinumab with that of other biological agents using
the Psoriasis Area and Severity Index (PASI) among adult patients with moderate to severe …

Importance Treatments for psoriasis may be less effective in everyday practice than in
clinical trials. Emulating a target trial using data from the British Association of …

Background Patients with moderate to severe psoriasis may not respond adequately to
single systemic agent and may require combination systemic therapy. Objective To evaluate …

Background The rapid expansion of psoriasis biologics has led to an urgent need to
understand their relative efficacy and tolerability to inform treatment decisions better and …

Objective: To systematically review the pharmacology, pharmacokinetics, clinical efficacy,
and safety profile of ustekinumab to inform pharmacists and other healthcare professionals …

A number of biologic agents, including the tumour necrosis factor (TNF) antagonists
etanercept, adalimumab and infliximab, and the interleukin (IL)‐12/IL‐23 antagonist …

Background Chronic plaque psoriasis is frequently associated with metabolic disorders
including obesity. Antitumour necrosis factor α treatments can induce body‐weight increase …

Letters to the Editor blockers, have also been approved in Taiwan for psoriasis patients who
failed previous phototherapy and pervious systemic therapy. Ustekinumab is a novel …